Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PA3-17 in CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies
NCT05170568Phase 1Unknown
- Sponsor
- PersonGen BioTherapeutics
- Start
- Dec 2021
- Primary completion
- Dec 2022
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PA3-17 in t-cell acute lymphoblastic leukemia (T-ALL) and T cell lymphoblastic lymphoma (T-LBL), sponsored by PersonGen BioTherapeutics. Primary endpoints: Dose-Limiting Toxicity at 28 days and Maximum Tolerated Dose at 2 years. Status: unknown.
02
Drugs
PA3-17
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT05170568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05170568.